Epigenetics

Syndicate content
Google News
Updated: 20 hours 24 min ago

?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution - WhatIsEpigenetics.com

Tue, 2019-06-04 10:10
?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution  WhatIsEpigenetics.com

The most common epigenetic mark throughout the genome is 5-methylcytosine (5mC). Additionally, 5-hydroxymethylcytosine (5hmC) is also known to play a ...

Zymo Research Recognized by NASA for its Support of Research Aboard the International Space Station - Yahoo Finance

Tue, 2019-06-04 09:08
Zymo Research Recognized by NASA for its Support of Research Aboard the International Space Station  Yahoo Finance

This device is a critical component for the research being conducted by The Human Health Countermeasures (HHC) Collaborative aboard the International ...

2019: Shedding light on the genetic causes of lung cancer - Environmental Factor Newsletter

Tue, 2019-06-04 09:06
2019: Shedding light on the genetic causes of lung cancer  Environmental Factor Newsletter

New findings from NIEHS researchers point to a novel strategy for preventing or treating a common type of lung cancer called lung squamous cell carcinoma ...

Image of the Month: The developing eye - Baylor College of Medicine News

Tue, 2019-06-04 09:00
Image of the Month: The developing eye  Baylor College of Medicine News

Microscopic image of the developing eye in a mouse embryo 11.5 days old.

?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution - WhatIsEpigenetics.com

Tue, 2019-06-04 01:00
?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution  WhatIsEpigenetics.com

The most common epigenetic mark throughout the genome is 5-methylcytosine (5mC). Additionally, 5-hydroxymethylcytosine (5hmC) is also known to play a ...

?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution - WhatIsEpigenetics.com

Tue, 2019-06-04 01:00
?DNA Deaminase-Based Hydroxymethyl–Seq: Nondestructive and Base-Resolution  WhatIsEpigenetics.com

The most common epigenetic mark throughout the genome is 5-methylcytosine (5mC). Additionally, 5-hydroxymethylcytosine (5hmC) is also known to play a ...

Global Epigenetic Market Size, Status, Application Specific Devices, Virtual Reality and Forecast 2019-2025 - News Tech Markets

Tue, 2019-06-04 00:36
Global Epigenetic Market Size, Status, Application Specific Devices, Virtual Reality and Forecast 2019-2025  News Tech Markets

This research report titled Global Epigenetic Market Size, Status and Forecast 2019-2025 has been added to the wide online database managed by Market ...

Epigenetics Market is gigantic to Grow at a high CAGR 4.8% over the forecast period 2019 and 2025: QYResearch - Spot Herld

Tue, 2019-06-04 00:21
Epigenetics Market is gigantic to Grow at a high CAGR 4.8% over the forecast period 2019 and 2025: QYResearch  Spot Herld

Los Angeles, June 04, 2019: Global Epigenetics market report is first of its kind research report that covers the overview, summary, market dynamics, competitive ...

Epigenetics Market Estimated To Witness a Phenomenal Growth by 2026 - Gator Ledger

Mon, 2019-06-03 20:19
Epigenetics Market Estimated To Witness a Phenomenal Growth by 2026  Gator Ledger

The global Epigenetics Market research report thoroughly explains each and every aspect related to the Epigenetics Market, which facilitates the report's reader ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - BioSpace

Mon, 2019-06-03 12:58
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  BioSpace

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...

Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting - PRNewswire

Mon, 2019-06-03 07:00
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting  PRNewswire

SAN DIEGO, June 3, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. presented updated results today at the 2019 ASCO Annual Meeting from the Ph1b portion ...